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Abstract: Purpose
Clostridium difficile is an important nosocomial pathogen in adults. Its significance in
children is less well defined, but cases of C. difficile infection (CDI) appear to be
increasingly prevalent in paediatric patients. This review aims to summarize reported
Clostridium difficile carriage rates across children of different age groups, appraise the
relationship between CDI and factors such as method of delivery, type of infant feed,
antibiotic use and co-morbidities and review factors affecting the gut microbiome in
children and the host immune response to C. difficile.
Methods
Searches of PubMed and Google Scholar using the terms 'Clostridium difficile
neonates' and 'Clostridium difficile children' were completed and reference lists of
retrieved publications screened for further papers. A total of 88 papers containing
relevant data were included.
Results
There was large inter-study variation in reported C. difficile carriage rates. There was
an association between CDI and recent antibiotic use, and co-morbidities such as
immunosuppression and inflammatory bowel disease. C. difficile was also found in
stools of children with diarrhoea attributed to other pathogens (e.g. rotavirus).
Conclusions
The role of C. difficile in the paediatric gut remains unclear; is it an innocent bystander
in diarrhoeal disease caused by other organisms or a pathogen causing subclinical to
severe symptoms? Further investigation of the development of serological and local
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host response to C. difficile carriage may shed new light on disease mechanisms.
Work is underway on defining a framework for diagnosis and management of
paediatric CDI.
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Dear Editorial team, 
 
Many thanks for your comments on our manuscript: The role of Clostridium difficile in the paediatric 
and neonatal gut - a narrative review. We have reviewed the comments on the initial draft of the 
manuscript and made the suggested changes as follows: 
 
Reviewer 1: 
References to 'NAP1/B1/027' have been corrected to 'BI' and the line referencing the TdC deletion 
theory removed. Antimicrobial names have been appropriately un-capitalised.  
In addition, comments have been added on the changing epidemiology of C. difficile to reference 
severity and community disease as well as the mortality with certain ribotypes  which was already 
mentioned. 
 
Reviewer 2: 
For those studies in which I was unable to determine exact numbers within each age group, there 
were alternate methods of detecting in which group most participants fell. For example, the Ellis 
paper, which I wished to include as it is a large, good quality study, there were graphs demonstrating 
patient age demographics, and though exact numbers in each group were not determinable from 
this, it was clear that only few participants were outside of the 1mth-1yr range. I was keen to include 
the 4 studies as I do feel they provide valuable data, and I am confident that participants in these 
studies were predominantly categorised into the correct age groups.   
I have added in further detail to make the comparator clear in the study highlighted on page 10.  
 
We look forwards to hearing from you if there are any further comments to address. 
 
 
Yours Faithfully, 
 
Emily Lees 
Authors' Response to Reviewers' Comments Click here to download Authors' Response to Reviewers'
Comments Response to reviewer comments.docx
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Abstract: 1 
Purpose 2 
Clostridium difficile is an important nosocomial pathogen in adults. Its significance in 3 
children is less well defined, but cases of C. difficile infection (CDI) appear to be increasingly 4 
prevalent in paediatric patients. This review aims to summarize reported Clostridium difficile 5 
carriage rates across children of different age groups, appraise the relationship between CDI 6 
and factors such as method of delivery, type of infant feed, antibiotic use and co-morbidities 7 
and review factors affecting the gut microbiome in children and the host immune response to 8 
C. difficile.   9 
Methods 10 
Searches of PubMed and Google Scholar using the terms ‘Clostridium difficile neonates’ and 11 
‘Clostridium difficile children’ were completed and reference lists of retrieved publications 12 
screened for further papers. A total of 88 papers containing relevant data were included.  13 
Results 14 
There was large inter-study variation in reported C. difficile carriage rates. There was an 15 
association between CDI and recent antibiotic use, and co-morbidities such as 16 
immunosuppression and inflammatory bowel disease. C. difficile was also found in stools of 17 
children with diarrhoea attributed to other pathogens (e.g. rotavirus).   18 
Conclusions 19 
The role of C. difficile in the paediatric gut remains unclear; is it an innocent bystander in 20 
diarrhoeal disease caused by other organisms or a pathogen causing subclinical to severe 21 
symptoms? Further investigation of the development of serological and local host response to 22 
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C. difficile carriage may shed new light on disease mechanisms. Work is underway on 1 
defining a framework for diagnosis and management of paediatric CDI.     2 
Background:  3 
Clostridium difficile (C. difficile) is a Gram-positive, anaerobic spore forming bacillus, which 4 
can exist as both toxigenic and non-toxigenic forms.[1] It has become a significant cause of 5 
nosocomial infection with high mortality rates, particularly in the elderly. There is increasing 6 
interest in the changing epidemiology of C. difficile; as mortality rates have risen in 7 
association with emergence of hypervirulent strains such as the toxinotype group V, PCR 8 
ribotype 078 (NAP7/BK/078) and North American toxinotype III, PCR ribotype 027 9 
(NAP1/BI/027), and there have been increasing rates of community-associated disease in 10 
recent years.[2] Approximately 4-5% of non-hospitalised healthy adults carry the organism in 11 
their intestinal flora.[3] In hospitalised adults and those in long term care facilities, the rate of 12 
asymptomatic carriage is estimated to be 20-50%,[4,5] and varying carriage rates of up to 70% 13 
have been reported in healthy newborns.[6] In children, there is a decreasing trend in carriage 14 
rate with increasing age; with colonisation falling to adult levels of around 5% by the age of 2 15 
years.  16 
C. difficile colonisation results in a spectrum of clinical conditions ranging from 17 
asymptomatic carrier state to fulminant colitis. The pathophysiology of C. difficile-associated 18 
diarrhoea requires alteration of the colonic microflora, colonisation by C. difficile and the 19 
release of enterotoxins from the toxigenic strains (typically Toxin A and Toxin B and in some 20 
instances a binary toxin).[1] The use of broad-spectrum antibiotics disturbs the indigenous 21 
intestinal microbiota, which eliminates competing microbes and allows C. difficile 22 
overgrowth and toxin production in the colon.  23 
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Researchers have tried to identify the differences in host mechanism between adult and 1 
paediatric populations, as C. difficile has traditionally been viewed as non-pathogenic in 2 
young infants; given that they may carry both toxigenic and non-toxigenic strains without 3 
overt clinical symptoms. One theory is that infants lack the mechanism for cellular 4 
internalization of the large clostridial toxins owing to their presumed lack of toxin receptors, 5 
which purportedly reach adult levels after weaning.[7] Some studies have considered the 6 
protective mechanisms of breast milk in C. difficile colonisation in comparison to artificial 7 
formula.[8,9] An in-vitro and in-vivo study showed that human colostrum contains neutralizing 8 
antibodies to toxin A and B.[6,10] A study examining the association between serum IgG 9 
antitoxin A levels and development of clinical symptoms found that adults with low or absent 10 
antibody levels were more likely to develop diarrhoea or colitis, whereas those with higher 11 
titres were more likely to exhibit asymptomatic carriage.[11] Similarly, relapse/recurrence of 12 
CDI occurred more frequently in individuals with lower levels of IgG/IgM to Toxin A,[12] but 13 
there are no reported data on when infants develop seropositivity to C. difficile antigens and 14 
whether this correlates with the clearing of the organism from the bowel flora or with 15 
symptomatic C. difficile infection.  16 
Concern about C. difficile disease in children has resurfaced due to the higher rates of 17 
infections and recurrence found in specific groups of children, such as children with 18 
haematological malignancies, inflammatory bowel disease (IBD) and cystic fibrosis 19 
following lung transplantation.[13] Although there have been a number of epidemiological 20 
studies performed in the United States[14] and Canada, large gaps in our knowledge remain as 21 
to the role of C. difficile and its interaction with other bowel flora in neonates and children. 22 
There is also controversy over whom to test for C. difficile, with the American Academy of 23 
Pediatrics releasing a policy statement in 2013 outlining when C. difficile testing should be 24 
considered in children; recommending avoidance of routine testing in children under 1 year 25 
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of age, due to their higher carriage rates. Between 1-3 years, testing may be considered, but 1 
testing for other pathogens (especially viral pathogens) should be prioritized. Over 3 years, it 2 
is advised that testing should be performed in the same circumstances as it would be in adults 3 
(i.e. acute diarrhoea and recent history of antibiotic use).[14]  4 
First line treatments for C. difficile disease are vancomycin or metronidazole, although in 22-5 
38% cases (particularly in severe disease), failure of treatment has been reported with 6 
metronidazole. Disease relapse/recurrence is also a concern with both drugs.[15] More 7 
recently, fidaxomicin; the first in a new class of macrocylic antimicrobials against C. difficile 8 
has been introduced with greater efficacy in patients with recurrent disease, though data is 9 
lacking in use for patients below 18 years of age.[16,17] Pharmacokinetic study of the drug in 10 
children 6 months – 18 years is underway in the USA (Clinicaltrials.gov: NCT01591863), but 11 
expert panel has suggested that there is no unmet need for a new treatment in children under 12 
2 years, given the lack of a clear case definition in this population.[18]  13 
In recent years, with rapid advances in genetic sequencing techniques, there has been 14 
increasing interest in the human gut microbiome.  The microbiome constitutes the many and 15 
varied microbes (including bacteria, viruses, archaea and fungi) that colonize the skin, oral 16 
cavity and gut shortly after birth in all humans.[19] These microbes are generally thought to be 17 
commensals, however their particular composition is thought to play a role in certain illnesses 18 
(e.g. IBD).[20,21] There is an association between reduced diversity of the gut microbiome, 19 
intestinal dysbiosis, C. difficile carriage[22] and C. difficile disease/recurrence in adults.[23] 20 
Analysis of C. difficile infected mice found that the microbiota consistently contained (in 21 
addition to C. difficile) opportunistic pathogens that have been identified within the 22 
microbiota of humans with CDI. These pathogens include: Klebsiella pneumoniae, Proteus 23 
mirabilis and Enterococcus faecalis.[22] Klebsiella pneumoniae and Ruminococcus gnavus 24 
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were noted to be associated with C. difficile carriage in an infant study, with Bifidobacterium 1 
longum appearing to have a protective role.[24] In addition, administration of targeted 2 
bacteriotherapy (with a mixture including Lactobacillus reuteri and Bacteroidetes sp. nov.) to 3 
mice with chronic CDI was able to eliminate disease and shedding by restoring a more 4 
diverse intestinal microbiota.[22]   5 
Objectives:  6 
The objectives of this review are: 7 
1) To summarise current available evidence on prevalence and distribution of C. difficile 8 
in neonates, infants and children. 9 
2) To ascertain the relationship between C. difficile infection (CDI) and factors such as 10 
delivery method, infant feed type, environmental exposure (e.g. time spent on NICU), 11 
antibiotic use and co-morbidities.  12 
3) To summarise risk factors for relapse of CDI and review factors affecting the gut 13 
microbiome in children and the immunological response to C. difficile in childhood. 14 
Methods: 15 
Search methods for identification of studies: 16 
Electronic searches: Searches of PubMed and Google Scholar were completed, using the 17 
terms ‘Clostridium difficile neonate/newborn/infant’ and ‘Clostridium difficile 18 
child/children’. The Cochrane Library and the Public Health England (formerly Health 19 
Protection Agency) websites were searched for current UK guidance on C. difficile infection. 20 
Reference lists of retrieved publications were screened for further papers. A total of 51 21 
articles containing epidemiological data on C. difficile were reviewed and included (see 22 
appendix 1 and Supplement 1).   Of these, 23 studies contained data for participants 0-1 23 
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month old, 18 for participants 1 month – 1 year old and 26 studies contained data for 1 
participants >1 year of age. Reported studies were conducted between 1981-2013, in diverse 2 
locations worldwide and in both high and low resource settings. Sample size ranged from 12 3 
to 1032 and a wide range of participants were involved, including: inpatients on Neonatal 4 
Intensive Care Unit (NICU) and post-natal wards, healthy outpatients, nursery attendees, 5 
hospitalised children with and without diarrhoea and immunocompromised children. In 6 
addition to these studies, 37 articles were identified that also provided data relevant to issues 7 
addressed in objectives 2 and 3. 8 
Data collection and analysis:  9 
Selection of studies: Studies were included if they were written in English and offered data 10 
on C. difficile prevalence in children, regardless of setting (i.e. inpatient/outpatient/healthy 11 
volunteer). Results of epidemiological studies were split into three age groups: neonates < 1 12 
month, infants 1month – 1 year and children >1 year of age. If the age range of patients was 13 
not specified, results were included in the category that contained the median and mean age 14 
(where recorded). If median and mean were not specified and the exact number of 15 
participants in each age group was not determined from the figures in each study, data were 16 
included in the group into which the greatest number of  patients appeared to fall (this 17 
occurred for 4 studies and these are highlighted in online supplement 1). The initial intention 18 
had been to determine rates specifically in the age group of children >2 years, to correspond 19 
with the current accepted lower age limit for C. difficile testing in most UK paediatric 20 
centres; however few studies included data on this age group separate from those >1year of 21 
age.  22 
Given the heterogeneous nature of the study populations, and lack of measurable health 23 
outcomes (given that some studies assessed C. difficile prevalence, whereas others treated 24 
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those with C. difficile as having disease), it was felt that a meta-analysis was not appropriate 1 
for these data. Data analysis was performed using STATA statistical software (release 14.0, 2 
STATA Corp., College Station, TX, USA) and Microsoft Excel. 3 
Results:   4 
Carriage rates in different age groups  5 
For each age group, there was a large disparity in rate of C. difficile colonisation (Figure 1); a 6 
volume effect was seen in larger studies, suggesting rates of 25-30% in neonates under 1 7 
month of age, 10-25% in infants 1 month - 1 year of age and 5-10% in children >1 year old; 8 
the latter value approaches the rate seen in adult studies. We also analysed data by location of 9 
patients tested; for neonates, the highest rates of colonisation were seen in patients on NICU 10 
(33%), suggesting persistence of C. difficile in the NICU environment, but high rates were 11 
also seen in healthy outpatients (27%) and on the postnatal ward (24%)(Figure 2). 12 
For infants 1 month – 1 year of age and those over 1 year of age, comparable rates of C. 13 
difficile were seen in hospitalised infants (26% and 12% respectively) and healthy outpatients 14 
(24% and 15% respectively). Interestingly, C. difficile was isolated least frequently in 15 
diarrhoeal outpatients (16% and 7% respectively).  16 
Association between environment, antibiotic use, infant feed type, delivery method and 17 
colonisation in neonates 18 
Environmental exposure 19 
Rates of C. difficile detection have been shown to increase with length of stay on the neonatal 20 
unit; some studies have also shown clear patterns of environmental contamination.[25,26] Kato 21 
et al reported a 61% colonisation rate of infants in a NICU, with 53 of 55 isolates from 30 22 
patients being identical and non-toxigenic, suggesting nosocomial spread on the NICU,[27] 23 
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whereas Merida et al found no carriage of C. difficile in term neonates born on a recently 1 
opened maternity unit, where it is likely that environmental contamination had not yet 2 
occurred.[28]  3 
Antibiotic use 4 
In a previous US study, antibiotic treatment for neonates on NICU was associated with a 5 
lower C. difficile colonisation rate,[29] but colonisation with C. difficile occurred rapidly after 6 
cessation of antibiotics. The presence of C. difficile colonisation and other faecal microflora 7 
is delayed in infants who receive antibiotic treatment.[30,31] There was an inverse correlation 8 
between gut diversity index (number and distribution of bacterial species in the gut) and 9 
number of days of antibiotics received in infants born between 27 and 29 weeks’ gestation, 10 
and weight gain increased with increased diversity scores.[32]  11 
None of the neonates in the studies reviewed were treated for C. difficile, with the exception 12 
of the study by Han et al,[33] where neonates admitted to NICU  who were found to carry C. 13 
difficile were treated with vancomycin due to an outbreak of necrotizing enterocolitis (NEC) 14 
attributed to C. difficile. However, since other bacterial gut pathogens were not investigated, 15 
a causal link here between C. difficile and NEC cannot be inferred. 16 
Method of infant feeding  17 
Penders et al,[34] found that in healthy 1 month old infants, who had not received antibiotics; 18 
twice as many formula-fed infants were colonised by C. difficile than those who were 19 
exclusively breast fed. Also, those breast-fed infants who were colonised by C. difficile had 20 
significantly lower colony counts than formula fed infants. These findings were replicated 21 
with a study of infants up to 1 year of age demonstrating colonisation rates of C. difficile to 22 
be 4 times higher in formula-fed infants than those who were exclusively breast-fed. Those 23 
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receiving both breast and formula feeds had intermediate colonisation rates.[8] A large 1 
Swedish study also found significantly more formula-fed infants under 6 months to be 2 
colonised with C. difficile.[9] Ruminococcus (which is more commonly found in the gut of 3 
breast-fed infants), is thought to inhibit growth of Clostridia, thereby preventing colonisation 4 
by C. difficile.[35]   5 
Mode of delivery  6 
A small UK study found 22% women had vaginal colonisation by C. difficile either pre- or 7 
post-delivery; of whom 89% delivered infants whose stools tested positive for C. difficile 8 
within 4 days of birth compared to a 56% detection rate in infants born to swab negative 9 
mothers.[36] These findings have not been replicated in other maternal studies.  10 
A delay in colonisation and alteration in composition of microbiota (with lower counts of 11 
Bifidobacteria) has been noted in babies delivered by caesarean section (CS) relative to those 12 
born by vaginal delivery.[37,38] Another study found lower bacterial counts until day 7 of life 13 
in infants delivered by planned caesarean (i.e. amniotic membranes intact and no exposure to 14 
vaginal/bowel flora).[39] This study, which sampled neonatal stools regularly over the period 15 
of one year, also demonstrated that whilst the broad groups of bacteria found in the GI tract 16 
were similar for each participant, there was a great degree of diversity and individuality in the 17 
combination of species that each infant acquired and their change over time. The microbiome 18 
was more stable than anticipated, even in the neonatal period, with certain colonizing bacteria 19 
being found in the stool repeatedly over a period of weeks or months. Fraternal twins had 20 
similar microbiomes, indicating the important influence of environment on colonisation. By 21 
one year of age, the microbiome was starting to resemble an adult profile, though 22 
interestingly, there were no great similarities between infants and their own parents.    23 
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A longitudinal study  of term infants born by CS (with prophylactic antibiotics) or vaginal 1 
delivery, noted significantly lower bacterial counts in the CS group, even at 6 months of age 2 
and delayed colonisation by Bacteroides. They were also significantly more likely to be 3 
colonised by Clostridium perfringens. No differences up to this point were noted in intestinal 4 
signs and symptoms, such as diarrhoea or colic.[40] A study recruiting healthy Finnish 5 
children at 7 years of age found significantly higher numbers of Clostridia in the stool of 6 
children delivered vaginally than those delivered by CS. This study suggests that method of 7 
delivery may have persistent effects on microbiota well beyond infancy.[41]  8 
C. difficile burden in children over 1 year 9 
In England, Wales & N. Ireland, in 2014, 257 cases of CDI were reported in children <15 10 
years, representing a 5.9% decrease on the previous year’s figures.[42] When analysed by age, 11 
rates of CDI were (expressed as cases per 100,000 population): < 2yr = 2.7, 2-4yr = 4.1, 5-12 
9yr = 1.8 and 10-14yr = 2.0.   13 
In a recent US-based study, the incidence of CDI in children had increased remarkably, from 14 
2.6 to 32.6 per 100,000 person-years between 1991-7 and 2004-9.[43] Cases were defined as 15 
diarrhoea with positive C. difficile enzyme immunoassay (EIA) or PCR and no other 16 
identifiable cause for diarrhoea. There was a sharp increase in cases from 2006-8, but the C. 17 
difficile detection method was altered from EIA to PCR in July 2007, suggesting increased 18 
case ascertainment with use of PCR. Of all cases, 75% were community-attributable, but 19 
interestingly, 85.5% of these patients had reported an ED or outpatient visit in the 3 months 20 
prior to disease onset.  21 
A 2014 Polish study reports rates of 13.5 cases of CDI per 1,000 children hospitalised with 22 
diarrhoea, however, not all children were tested for viral/alternative bacterial pathogens, and 23 
those who were co-infected with C. difficile and another pathogen were recorded as being a 24 
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case of CDI.[44] Indeed, a recent literature review on co-infections in children with C. difficile 1 
notes a rate of 20.7% (range 0-100%) for reported co-infections (predominantly viral 2 
infections), but found it difficult to draw any meaningful conclusions, given the heterogeneity 3 
between studies as to which organisms were tested for (virus/bacteria/parasite) and the 4 
difficulty in describing what constitutes CDI in the paediatric population.[45] 5 
Where data on treatment of cases was available for C. difficile positive subjects in the studies 6 
reviewed here of infants 1 month – 1 year or children >1 year, 23 of 968 cases (2.4%) aged 1 7 
month – 1 year and 86/368 (23.4%) >1 year received treatment with metronidazole and/or 8 
vancomycin for their suspected CDI.  9 
A recent study of adults in Oxfordshire (UK) noted a decrease in prevalence of the 10 
hypervirulent ST1/NAP/027 strain, which was proposed to be due to improved antibiotic 11 
stewardship and infection control measures. Interestingly, this study also found a fairly 12 
diverse reservoir of C. difficile subtypes (with 45% of CDI cases being genetically distinct 13 
from one another), and a further 36% patients with CDI from genetically similar strains 14 
having no hospital or community contact with one another.[46] This suggests the existence of 15 
other reservoirs for infection, possibly asymptomatically colonised infants.  Contact with 16 
children under 2 years of age has also been linked with CDI in adults with community-17 
acquired disease, with 14% of cases vs. 2% of controls having reported contact with a child 18 
under 2.[47] 19 
Risk factors for C. difficile infection (CDI) 20 
In the US, 57% to 75% of paediatric patients with community-acquired CDI reported 21 
antibiotic use in the 3 months prior to admission.[48] In children hospitalised with CDI, 22 
exposure to 3 antibiotic classes in the month prior to admission was associated with severe 23 
disease, as was malignancy.[49] No association was found with age, prematurity (delivery <37 24 
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weeks’ gestation), GI surgery or steroid/immunosuppressant use for 2 weeks in the month 1 
preceding diagnosis. Other studies have shown a strong link between immunosuppression and 2 
severe illness with CDI.[50,51] Inflammatory bowel disease (IBD), [52] intestinal stasis 3 
(Hirschsprung’s disease),[13] organ transplant and gastrostomy/jejunostomy and Cystic 4 
Fibrosis[53] have all been implicated in the development of CDI.[48] Indeed, the first 5 
presentation of IBD could appear clinically similar to that of C. difficile enterocolitis.  A US 6 
study found a significantly increased incidence of C. difficile in children >3 years with 7 
previous  antibiotic exposure (35% exposed vs. 2% unexposed).[54] Another study reported 8 
association between community-acquired CDI and Cephalosporin use within 30 days (OR 9 
3.32; 95% CI: 1.10-10.01) and presence of a gastrointestinal feeding device (OR 2.59; 95% 10 
CI: 1.07-6.30).[55]  11 
Elevated gastric pH has been hypothesized to influence CDI risk by facilitating bacterial 12 
colonisation of the upper gastrointestinal tract and/or survival of the vegetative phase of C. 13 
difficile in the stomach. An Italian paediatric retrospective case-control study found a 14 
significant association between proton-pump inhibitor (PPI) usage and CDI (PPI use in 15 
22.1% C. difficile positive vs. 5.9% C. difficile negative patients) and a non-significant 16 
association between H2-receptor antagonists and CDI (10.3% vs. 2.9%).[56]  17 
There have also been reports of CDI associated with viral gastroenteritis (norovirus and 18 
caliciviruses), with a suggested mechanism of inflammation of the intestinal epithelium 19 
following gastroenteritis facilitating adherence and colonisation by C. difficile and the 20 
attachment of its toxins.[57,58] In an Italian study, co-infection with multiple pathogens was 21 
seen in 27 of 151 patients (18%); with the most common co-infections being rotavirus and 22 
toxin-producing C. difficile, accounting for 63% of co-infections.[59] Children with co-23 
infection had a higher incidence of severe disease and were more likely to be dehydrated on 24 
presentation. There was no significant age difference between those with and without co-25 
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infection. All cases of C. difficile occurred in children under 6 years, with the majority being 1 
concentrated in the youngest group (under 2 years). Conversely, another study noted that 2 
diarrhoeal children with viral co-infections tended to have higher C. difficile bacterial burden 3 
(median difference = 565,957 cfu/mL; p = 0.011), but were clinically indistinguishable from 4 
those with C. difficile alone.[60] Similarly, an Italian study found no significant difference in 5 
clinical presentation in children with prolonged/mucohaemorrhagic diarrhoea by C. difficile 6 
status.[61]  The significance of detecting C. difficile in the presence of known pathogenic 7 
viruses remains unclear.  8 
Relapsing infection in children 9 
Relapses and/or recurrences have been reported in up to 25% of paediatric CDI cases,[62] 10 
which is in line with 20-30% seen in adult studies.[63] In adults, relapse has been associated 11 
with lower blood concentrations of anti-toxin A and B antibody and the presence of strain 12 
BI/NAP1/027.[11,64] This has led to use of pooled intravenous immunoglobulins (IVIg) and 13 
anti-toxin monoclonal antibodies in recurrent, refractory or severe disease. There has been 14 
little work done in children, but a small study by Leung et al reported lower serum levels of 15 
IgG for TcdA in children with relapsing C. difficile-associated colitis than healthy children, 16 
with symptoms ameliorating following IVIg infusions.[65] There was however no control 17 
group in this study so it is difficult to infer causation; although a study of CDI in children 18 
found that transient hypogammaglobulinaemia of infancy was significantly associated with 19 
recurrent disease, adding credence to this theory.[66] 20 
The reported incidence of complications with CDI in children (e.g. renal failure, bowel 21 
perforation, death) is lower than that in adults; varying between 0-12%.[67] However, it is 22 
difficult to classify C. difficile disease in children as there is no validated paediatric tool and 23 
current guidance comes from the adult classification systems. One retrospective paediatric 24 
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study found that although 76% of the cases seen in their hospital would be classified as 1 
severe using adult guidelines, most cases experienced a fairly mild illness with low morbidity 2 
and mortality.[68] The majority of patients in this study had not been treated or were given 3 
probiotics or metronidazole with good recovery, despite their ‘severe’ classification. The 4 
authors proposed new disease classification criteria for children, which are currently 5 
undergoing prospective validation.  6 
Faecal biomarkers and paediatric CDI 7 
Faecal C. difficile bacterial load does not appear to differ between symptomatic and 8 
asymptomatic children and does not correlate with outcome.[69] In this study, faecal levels of 9 
lactoferrin and cytokines (CXCL-5, IL-8) were elevated in C. difficile-positive compared to 10 
C. difficile-negative children with diarrhoea, and time to diarrhoea resolution after treatment 11 
was significantly longer in those with elevated faecal CXCL-5 mRNA, and IL-8 mRNA at 12 
diagnosis (medians of 7 vs 2 days and 5 vs 3 days respectively). A relatively small sample 13 
size of 102 may limit further generalization from this study’s results. Similarly, 14 
immunosuppressed CDI patients had lower IL-8 mRNA expression than immunocompetent 15 
patients.  16 
Serological response to exposure to C. difficile 17 
A study of infants under 6 months of age found that 11% and 33% had detectable levels of 18 
serum IgG against toxins A and B respectively. Prevalence of serum anti-toxin IgG to both 19 
toxins increased throughout childhood, reaching 25% (Toxin A) and 53% (Toxin B) by 2 20 
years.[70] Likelihood of strongly reactive antibodies (as measured by ELISA values) also 21 
increased with age over 2 years. Interestingly, those who produced a strong antibody 22 
response against Toxin A were less likely to produce an equivalent response against toxin B 23 
and vice versa.  24 
16 
 
Conclusions: 1 
It is accepted that C. difficile is present relatively frequently in neonates, though its 2 
significance and effects on the microbiota in later life have yet to be determined. Possible 3 
hypotheses for lack of C. difficile disease in this population include: immaturity of  bowel 4 
mucosa with a lack of receptors for C. difficile toxins, immunoglobulin fractions present in 5 
breast milk preventing binding of toxins to their receptors as well as the nature and 6 
composition of infant gut microflora being protective against C. difficile overgrowth.[71] 7 
Further studies are needed to determine the significance of asymptomatic C. difficile 8 
colonisation and consequent changes in the microbiota throughout infancy and childhood and 9 
into later life. 10 
There is a huge body of literature on C. difficile infection in adults, and now an expanding 11 
body of work on its role in children. There remains a great deal of disagreement on what 12 
constitutes paediatric C. difficile infection, and the differentiation between symptomatic 13 
manifestation and what is believed to be presence of the organism as a bystander in diarrheal 14 
disease caused by other organisms. A collaborative policy document published by the Society 15 
for Healthcare Epidemiology of America supports this view that in the setting of high 16 
prevalence of asymptomatic carriage, C. difficile cannot be assumed to be the causative agent 17 
of diarrhoea prior to adolescence (particularly in younger children).[72]  18 
Defining paediatric CDI is further complicated by the lack of a standardized scoring system 19 
for paediatric infection, making it more difficult to quantify disease burden in those thought 20 
to have CDI and thus to know whom to treat. Crews et al[55] suggest a framework as to how 21 
severity of disease may be defined in children, and clearly consideration of the presence of 22 
risk factors should play an additional role in ascertaining the likelihood of CDI versus 23 
incidental finding. Given the consensus that children who do have CDI run a much milder 24 
17 
 
disease course than adults, it is appropriate to tailor treatment as such, with the first steps 1 
being supportive care (rehydration) and discontinuation of unnecessary antibiotics, or at least 2 
narrowing spectrum and reviewing course length, prior to considering active treatment with 3 
metronidazole/vancomycin.    4 
Longitudinal exploration of the role of the intestinal microbiota and the development of 5 
serological host response to C. difficile during carriage and disease and the age at which this 6 
occurs would prove valuable approaches to this issue. This, alongside more detailed work on 7 
local gut response to C. difficile in diarrheal children would provide a firm basis for the 8 
mechanistic understanding of pathogenesis of CDI in early life. Further work is also 9 
warranted on the hypothesis that children are a major community reservoir for community-10 
attributable CDI cases in adults, as this would have important public health implications.       11 
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Appendix 1: Study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies identified through database 
searching, n = 471 
Additional studies identified 
through other methods, n = 12 
Studies screened by title or 
abstract, n = 483 
Studies excluded (irrelevant / not in 
English), n = 261 
Full text studies evaluated for 
inclusion, n = 222 
Studies excluded (full text not 
available / study irrelevant / results 
not interpretable), n = 134 
Studies included – provided data for 
objective 1 (n = 51), provided data 
for objectives 2 & 3 (n= 37) 
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